Back to search results

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

Israel
RecruitingPHASE2

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Conditions

Ovarian Neoplasms · Breast Neoplasms

Locations
  • GSK Investigational Site, Tucson, Arizona, United States
  • GSK Investigational Site, Encinitas, California, United States
  • GSK Investigational Site, Los Angeles, California, United States
  • GSK Investigational Site, Whittier, California, United States
  • GSK Investigational Site, Jacksonville, Florida, United States
  • GSK Investigational Site, Atlanta, Georgia, United States
  • GSK Investigational Site, Harvey, Illinois, United States
  • GSK Investigational Site, Boston, Massachusetts, United States
  • GSK Investigational Site, Grand Rapids, Michigan, United States
  • GSK Investigational Site, Morristown, New Jersey, United States
  • GSK Investigational Site, Lake Success, New York, United States
  • GSK Investigational Site, Charlotte, North Carolina, United States
  • GSK Investigational Site, Cleveland, Ohio, United States
  • GSK Investigational Site, Graz, Austria
  • GSK Investigational Site, Vienna, Austria
  • GSK Investigational Site, Kelowna, British Columbia, Canada
  • GSK Investigational Site, Toronto, Ontario, Canada
  • GSK Investigational Site, Montreal, Quebec, Canada
  • GSK Investigational Site, Odense C, Denmark
  • GSK Investigational Site, Nantes, France
  • GSK Investigational Site, Nice, France
  • GSK Investigational Site, Haifa, Israel
  • GSK Investigational Site, Cremona, Italy
  • GSK Investigational Site, Madrid, Spain
  • GSK Investigational Site, Madrid, Spain
View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)